StemCells names president & COO

Newark, California-based StemCells, a company developing novel cell-based therapeutics for disorders of the central nervous system, has named Ian Massey president and chief operating officer. In this new role, Dr Massey has direct responsibility for all aspects of the company's R&D, manufacturing, regulatory affairs and quality assurance activities. He will report to StemCells' CEO Martin McGlynn. Most recently, Dr Massey was the COO and president of US operations at Biotie Therapies, a publicly traded Finnish company focused on neurodegenerative and psychiatric disorders.